TY - JOUR
T1 - Exome sequencing of choreoacanthocytosis reveals novel mutations in VPS13A and co-mutation in modifier gene(s)
AU - Chaudhari, Sima
AU - Ware, Akshay Pramod
AU - Jasti, Dushyanth Babu
AU - Gorthi, Sankar Prasad
AU - Acharya, Lavanya Prakash
AU - Bhat, Manoj
AU - Mallya, Sandeep
AU - Satyamoorthy, Kapaettu
N1 - Funding Information:
Open access funding provided by Manipal Academy of Higher Education, Manipal. This project is funded by DST-UKIERI grant (DST/INT/UK/P-147/2016) from Government of India.
Funding Information:
We thank DST-UKIERI for the financial support, Indian Council of Medical Research—Senior research fellowship provided to Sima Chaudhari, and Dr TMA Pai Ph.D. fellowships provided to Akshay Pramod Ware. We also thank Technology Information, Forecasting and Assessment Council-Centre of Relevance & Excellence (TIFAC-CORE), DBT-Builder, Manipal Academy of Higher Education (MAHE) and Manipal School of Life Sciences for infrastructure support.
Funding Information:
We thank DST-UKIERI for the financial support, Indian Council of Medical Research—Senior research fellowship provided to Sima Chaudhari, and Dr TMA Pai Ph.D. fellowships provided to Akshay Pramod Ware. We also thank Technology Information, Forecasting and Assessment Council-Centre of Relevance & Excellence (TIFAC-CORE), DBT-Builder, Manipal Academy of Higher Education (MAHE) and Manipal School of Life Sciences for infrastructure support.
Publisher Copyright:
© 2023, The Author(s).
PY - 2023/7
Y1 - 2023/7
N2 - Choreoacanthocytosis, one of the forms of neuroacanthocytosis, is caused by mutations in vacuolar protein sorting-associated protein A (VPS13A), and is often misdiagnosed with other form of neuroacanthocytosis with discrete genetic defects. The phenotypic variations among the patients with VPS13A mutations significantly obfuscates the understanding of the disease and treatment strategies. In this study, two unrelated cases were identified, exhibiting the core phenotype of neuroacanthocytosis but with considerable clinical heterogeneity. Case 1 presented with an additional Parkinsonism phenotype, whereas seizures were evident in case 2. To decipher the genetic basis, whole exome sequencing followed by validation with Sanger sequencing was performed. A known homozygous pathogenic nonsense mutation (c.799C > T; p.R267X) in exon 11 of the VPS13A gene was identified in case 1 that resulted in a truncated protein. A novel missense mutation (c.9263T > G; p.M3088R) in exon 69 of VPS13A identified in case 2 was predicted as pathogenic. In silico analysis of the p.M3088R mutation at the C-terminus of VPS13A suggests a loss of interaction with TOMM40 and may disrupt mitochondrial localization. We also observed an increase in mitochondrial DNA copy numbers in case 2. Mutation analysis revealed benign heterozygous variants in interacting partners of VPS13A such as VAPA in case 1. Our study confirmed the cases as ChAc and identified the novel homozygous variant of VPS13A (c.9263T > G; p.M3088R) within the mutation spectrum of VPS13A-associated ChAc. Furthermore, mutations in VPS13A and co-mutations in its potential interacting partner(s) might contribute to the diverse clinical manifestations of ChAc, which requires further study.
AB - Choreoacanthocytosis, one of the forms of neuroacanthocytosis, is caused by mutations in vacuolar protein sorting-associated protein A (VPS13A), and is often misdiagnosed with other form of neuroacanthocytosis with discrete genetic defects. The phenotypic variations among the patients with VPS13A mutations significantly obfuscates the understanding of the disease and treatment strategies. In this study, two unrelated cases were identified, exhibiting the core phenotype of neuroacanthocytosis but with considerable clinical heterogeneity. Case 1 presented with an additional Parkinsonism phenotype, whereas seizures were evident in case 2. To decipher the genetic basis, whole exome sequencing followed by validation with Sanger sequencing was performed. A known homozygous pathogenic nonsense mutation (c.799C > T; p.R267X) in exon 11 of the VPS13A gene was identified in case 1 that resulted in a truncated protein. A novel missense mutation (c.9263T > G; p.M3088R) in exon 69 of VPS13A identified in case 2 was predicted as pathogenic. In silico analysis of the p.M3088R mutation at the C-terminus of VPS13A suggests a loss of interaction with TOMM40 and may disrupt mitochondrial localization. We also observed an increase in mitochondrial DNA copy numbers in case 2. Mutation analysis revealed benign heterozygous variants in interacting partners of VPS13A such as VAPA in case 1. Our study confirmed the cases as ChAc and identified the novel homozygous variant of VPS13A (c.9263T > G; p.M3088R) within the mutation spectrum of VPS13A-associated ChAc. Furthermore, mutations in VPS13A and co-mutations in its potential interacting partner(s) might contribute to the diverse clinical manifestations of ChAc, which requires further study.
UR - https://www.scopus.com/pages/publications/85160272134
UR - https://www.scopus.com/pages/publications/85160272134#tab=citedBy
U2 - 10.1007/s00438-023-02032-2
DO - 10.1007/s00438-023-02032-2
M3 - Article
C2 - 37209156
AN - SCOPUS:85160272134
SN - 1617-4615
VL - 298
SP - 965
EP - 976
JO - Molecular Genetics and Genomics
JF - Molecular Genetics and Genomics
IS - 4
ER -